- RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This study is looking at new medicines (frexalimab, brivekimig, or rilzabrutinib) for kidney conditions called Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD). It aims to see if these medicines are safe and can help improve kidney function compared to a dummy drug.
For: Focal Segmental Glomerulosclerosis · Glomerulonephritis Minimal LesionUnited States · Argentina · Australia - RecruitingPHASE3
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
This study is for adults with a blood condition called Immune Thrombocytopenia (ITP) who haven't responded well to their first treatment. It looks at a new medicine called rilzabrutinib to see how well it works and if it's safe. It's a Phase 3 trial, meaning it's in a later stage of testing.
For: Immune ThrombocytopeniaUnited States · Austria · France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib (PRN1008), an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenia
This study is testing a new oral medicine, Rilzabrutinib, for adults with a blood condition called Immune Thrombocytopenia (ITP). It aims to see if the medicine is safe, how much to give, and if it helps increase platelet counts to reduce bleeding.
For: Immune ThrombocytopeniaCzechia · Netherlands · Bulgaria - Active not recruitingPHASE2
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
This study is looking into a new medication called rilzabrutinib for adults in the UK with warm autoimmune hemolytic anemia (wAIHA). It will check if the treatment is safe, how well it works, and how the body handles it. Participants will take the medication by mouth.
For: Warm Autoimmune Hemolytic Anemia (wAIHA)United States · Austria · China - RecruitingPHASE3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
This study looks at a new drug, Rilzabrutinib, for people aged 10-65 with sickle cell disease. We'll see how well it works and if it's safe compared to a dummy pill to help reduce painful crises.
For: Sickle Cell DiseaseUnited States · Belgium · Brazil - RecruitingPHASE3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This study is looking into a new medication, rilzabrutinib, for adults with a condition called IgG4-related disease. It compares the medication to a dummy pill to see if it's safe and helps control the disease over 52 weeks.
For: Immunoglobulin G4 Related DiseaseUnited States · Argentina · Belgium - Active not recruitingPHASE3
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
This study tested a new medicine, rilzabrutinib, for adults and teenagers with a blood condition called Immune Thrombocytopenia (ITP). It aimed to see if the medicine could help increase platelet counts, which are important for stopping bleeding.
For: Immune ThrombocytopeniaUnited States · Argentina · Australia